Management of Atypical Glandular Cells (AGC) with Concurrent ASC‑H and Positive High‑Risk HPV
Immediate Diagnostic Workup
- Women ≥ 25 years old with both AGC and ASC‑H on Pap and a positive high‑risk HPV test should undergo immediate colposcopy with endocervical sampling; endometrial sampling is added when the patient is ≥ 35 years or has risk factors for endometrial cancer. 1
- Colposcopy with endocervical sampling is required for all AGC cases, irrespective of HPV status or the presence of concurrent squamous abnormalities. 3
- Endometrial sampling must be performed when the patient is ≥ 35 years old or, if younger, has unexplained vaginal bleeding or risk factors for endometrial malignancy. 1
- Reflex HPV testing or repeat cytology alone is unacceptable as the initial triage strategy for AGC. 3
Risk Stratification
- ASC‑H carries up to a 50 % risk of underlying CIN 2/3. 3
- AGC is associated with significant squamous or glandular lesions in up to 38 % of cases, although most findings are benign. 1
- When AGC co‑exists with a positive HPV test, the positive predictive value for CIN 3 or invasive cancer is ≈ 20 % on biopsy. 1
Colposcopic Evaluation Components
- Endocervical curettage or cytobrush sampling is mandatory when evaluating AGC. 1
Post‑Colposcopy Management
- If the initial HPV test was positive, repeat cytology and HPV testing at 6 months is recommended. 1
- If the initial HPV test was negative, repeat cytology and HPV testing at 12 months is recommended. 1
- Annual cytologic screening may resume only after both HPV testing and cytology are negative on follow‑up. 1
Management of AGC‑favor Neoplasia / AIS
- When AGC‑favor neoplasia or adenocarcinoma in situ (AIS) is diagnosed, an excisional procedure (e.g., conization) may be required for complete evaluation even if colposcopic findings are negative. 1
Common Pitfalls to Avoid
- Do not base management solely on the ASC‑H component; the presence of AGC mandates aggressive evaluation, including endocervical and, when indicated, endometrial sampling. 1
- Do not defer colposcopy in favor of repeat cytology or HPV testing; immediate colposcopy is mandatory for any AGC finding. 3
- Do not omit endometrial sampling in women ≥ 35 years, as about 7 % of post‑menopausal women with benign‑appearing endometrial cells harbor significant pathology. 1
Age‑Specific Considerations
Women 25–34 years
- Cervical intraepithelial neoplasia (CIN) is the most common pathology underlying AGC in this age group. 1
- Endometrial sampling is not routinely required unless there is unexplained vaginal bleeding or specific endometrial cancer risk factors. 1